Olivier Blin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7248738/publications.pdf

Version: 2024-02-01

114	3,750	32	55
papers	citations	h-index	g-index
130	130	130	6130 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. Magnetic Resonance Imaging, 2021, 76, 108-115.	1.8	24
2	RNA therapeutics for mood disorders: current evidence toward clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 721-736.	4.1	2
3	Development and Validation of a Simple and Rapid Ultrahigh-Performance Liquid Chromatography Tandem Spectrometry Method for the Quantification of Hydroxychloroquine in Plasma and Blood Samples in the Emergency Context of SARS-CoV-2 Pandemic. Therapeutic Drug Monitoring, 2021, 43, 570-576.	2.0	7
4	Convergent and Discriminant Validity of Default Mode Network and Limbic Network Perfusion in Amnestic Mild Cognitive Impairment Patients. Journal of Alzheimer's Disease, 2021, 82, 1797-1808.	2.6	4
5	Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients. Expert Opinion on Pharmacotherapy, 2021, 22, 2507-2519.	1.8	1
6	Polyaminosteroid Analogues as Potent Antibacterial Agents Against Mupirocin-Resistant Staphylococcus aureus Strains. Anti-Infective Agents, 2020, 18, 239-244.	0.4	1
7	CSF cutoffs for MCI due to AD depend on APOEε4 carrier status. Neurobiology of Aging, 2020, 89, 55-62.	3.1	11
8	Modular slowing of resting-state dynamic functional connectivity as a marker of cognitive dysfunction induced by sleep deprivation. Neurolmage, 2020, 222, 117155.	4.2	24
9	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	2.6	7
10	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	2.6	13
11	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. Neurolmage, 2020, 218, 116932.	4.2	38
12	An Alzheimer Disease Challenge Model: 24-Hour Sleep Deprivation in Healthy Volunteers, Impact on Working Memory, and Reversal Effect of Pharmacological Intervention. Journal of Clinical Psychopharmacology, 2020, 40, 222-230.	1.4	10
13	Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections. British Journal of Clinical Pharmacology, 2020, 86, 2319-2324.	2.4	3
14	Dynamic Functional Connectivity as a complex random walk: Definitions and the dFCwalk toolbox. MethodsX, 2020, 7, 101168.	1.6	14
15	Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. Journal of Alzheimer's Disease, 2019, 69, 3-14.	2.6	18
16	Sleep deprivation and Modafinil affect cortical sources of resting state electroencephalographic rhythms in healthy young adults. Clinical Neurophysiology, 2019, 130, 1488-1498.	1.5	10
17	Staphylococcus aureus nasal decolonization strategies: a review. Expert Review of Anti-Infective Therapy, 2019, 17, 327-340.	4.4	34
18	One Step Forward Toward a Surrogate Endpoint for Clinical Trials of Alzheimer's Disease Drugs: The Results of PharmaCog WP5 (European ADNI). Journal of Alzheimer's Disease, 2019, 69, 1-2.	2.6	3

#	Article	IF	Citations
19	Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 49-58.	2.6	8
20	Plasma AÎ ² 42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. Journal of Alzheimer's Disease, 2019, 69, 37-48.	2.6	23
21	Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. Journal of Alzheimer's Disease, 2019, 69, 15-35.	2.6	34
22	Prolonged continuous wound infiltration with a local anaesthetic after total mastectomy: pharmacokinetics and preliminary results on postoperative pain. Anaesthesia, Critical Care & Deliminary Pain Medicine, 2019, 38, 385-386.	1.4	1
23	A 15-day course of donepezil modulates spectral EEG dynamics related to target auditory stimuli in young, healthy adult volunteers. Clinical Neurophysiology, 2019, 130, 863-875.	1.5	5
24	Effect of desipramine on patients with breathing disorders in <scp>RETT</scp> syndrome. Annals of Clinical and Translational Neurology, 2018, 5, 118-127.	3.7	15
25	Ropivacaine Wound Infiltration for Pain Management After Breast Cancer Mastectomy: A Population Pharmacokinetic Analysis. Clinical Pharmacology in Drug Development, 2018, 7, 811-819.	1.6	4
26	Impaired cortico-limbic functional connectivity in schizophrenia patients during emotion processing. Social Cognitive and Affective Neuroscience, 2018, 13, 381-390.	3.0	17
27	Brain Networks are Independently Modulated by Donepezil, Sleep, and Sleep Deprivation. Brain Topography, 2018, 31, 380-391.	1.8	27
28	Perampanel-associated self-harm ideation after dosage increase. European Journal of Clinical Pharmacology, 2018, 74, 243-244.	1.9	3
29	Staphylococcus aureus Nasal Colonization: An Update on Mechanisms, Epidemiology, Risk Factors, and Subsequent Infections. Frontiers in Microbiology, 2018, 9, 2419.	3.5	303
30	Cannabis smoking impairs driving performance on the simulator and real driving: a randomized, doubleâ€blind, placeboâ€controlled, crossover trial. Fundamental and Clinical Pharmacology, 2018, 32, 558-570.	1.9	34
31	Population pharmacokinetic model for tumescent lidocaine in women undergoing breast cancer surgery. European Journal of Clinical Pharmacology, 2018, 74, 1309-1315.	1.9	2
32	Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies. Clinical Pharmacokinetics, 2017, 56, 127-138.	3. 5	56
33	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiology of Aging, 2017, 53, 1-10.	3.1	59
34	Phenobarbital in intensive care unit pediatric population: predictive performances of population pharmacokinetic model. Fundamental and Clinical Pharmacology, 2017, 31, 558-566.	1.9	9
35	Childhood trauma and emotional processing circuits in schizophrenia: A functional connectivity study. Schizophrenia Research, 2017, 184, 69-72.	2.0	33
36	Neuropsychiatric events and dolutegravir in HIV patients. Aids, 2017, 31, 1775-1777.	2.2	18

#	Article	IF	CITATIONS
37	Long-term use of antipsychotics in community-dwelling dementia patients. International Clinical Psychopharmacology, 2017, 32, 13-19.	1.7	6
38	Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology. Fundamental and Clinical Pharmacology, 2017, 31, 685-694.	1.9	8
39	Comment on "Patient Reporting in the EU: Analysis of EudraVigilance Data― Drug Safety, 2017, 40, 935-936.	3.2	2
40	Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. British Journal of Clinical Pharmacology, 2017, 83, 1039-1047.	2.4	12
41	Antidepressant adherence patterns in older patients: use of a clustering method on a prescription database. Fundamental and Clinical Pharmacology, 2017, 31, 226-236.	1.9	11
42	Levodopa in Parkinson's Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis. Journal of Pharmacy and Pharmaceutical Sciences, 2017, 20, 226.	2.1	13
43	A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients. PLoS ONE, 2017, 12, e0169878.	2.5	10
44	Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette. Journal of Pharmacy and Pharmaceutical Sciences, 2016, 19, 411.	2.1	19
45	Simultaneous determination of four antiepileptic drugs in human plasma samples using an ultraâ€highâ€performance liquid chromatography tandem mass spectrometry method and its application in therapeutic drug monitoring. Biomedical Chromatography, 2016, 30, 2053-2060.	1.7	17
46	Baseline CSF AÎ ² , AÎ ² /T-TAU and AÎ ² /P-tau distributions to classify pharmacog MCI patients. Neurobiology of Aging, 2016, 39, S30.	3.1	0
47	Relation between facial affect recognition and configural face processing in antipsychotic-free schizophrenia Neuropsychology, 2015, 29, 197-204.	1.3	14
48	Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite <scp>E</scp> uropean 3T study on healthy elderly. Human Brain Mapping, 2015, 36, 3516-3527.	3.6	34
49	Effect of trait anxiety on prefrontal control mechanisms during emotional conflict. Human Brain Mapping, 2015, 36, 2207-2214.	3.6	28
50	Acute stress disorder modifies cerebral activity of amygdala and prefrontal cortex. Cognitive Neuroscience, 2015, 6, 39-43.	1.4	19
51	CX3CR1 is dysregulated in blood and brain from schizophrenia patients. Schizophrenia Research, 2015, 168, 434-443.	2.0	49
52	Clinical spectrum and gender differences in a large cohort of Charcot–Marie–Tooth type 1A patients. Journal of the Neurological Sciences, 2014, 336, 155-160.	0.6	22
53	Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus. Neuropharmacology, 2014, 85, 206-214.	4.1	21
54	Telemedicine: What Framework, What Levels of Proof, Implementation Rules. Therapie, 2014, 69, 347-354.	1.0	2

#	Article	IF	Citations
55	A Review of the Effects of Hypoxia, Sleep Deprivation and Transcranial Magnetic Stimulation on EEG Activity in Humans: Challenges for Drug Discovery for Alzheimer's Disease. Current Alzheimer Research, 2014, 11, 501-518.	1.4	18
56	Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease. Current Medical Research and Opinion, 2013, 29, 23-31.	1.9	21
57	Relationship between emotional experience and resilience: An fMRI study in fire-fighters. Neuropsychologia, 2013, 51, 845-849.	1.6	35
58	Brain morphometry reproducibility in multi-center 3T MRI studies: A comparison of cross-sectional and longitudinal segmentations. NeuroImage, 2013, 83, 472-484.	4.2	157
59	Synaptic function as a preclinical and experimental medicine readout for disease-modifying therapy in Alzheimer's Disease. Drug Discovery Today: Therapeutic Strategies, 2013, 10, e99-e104.	0.5	2
60	Emotional Reactivity Assessment of Healthy Elderly with an Emotion-Induction Procedure. Experimental Aging Research, 2013, 39, 109-124.	1.2	8
61	Clinical innovation for neurodegenerative diseases. Clinical Investigation, 2012, 2, 663-665.	0.0	6
62	Voluntary Emotion Suppression Modifies Psychophysiological Responses to Films. Journal of Psychophysiology, 2012, 26, 116-123.	0.7	17
63	Neuroticism Modifies Psychophysiological Responses to Fearful Films. PLoS ONE, 2012, 7, e32413.	2.5	43
64	Attentional bias in post-traumatic stress disorder diminishes after symptom amelioration. Behaviour Research and Therapy, 2011, 49, 796-801.	3.1	49
65	Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Bayesian Metaanalysis. Journal of Rheumatology, 2011, 38, 835-845.	2.0	45
66	Use of intravenous immunoglobulins in clinical practice: data from three French university hospitals. Fundamental and Clinical Pharmacology, 2011, 25, 753-761.	1.9	18
67	Amygdala activity correlates with attentional bias in PTSD. Neuropsychologia, 2011, 49, 1969-1973.	1.6	88
68	Effects of paroxetine on emotional functioning and treatment awareness: a 4-week randomized placebo-controlled study in healthy clinicians. Psychopharmacology, 2010, 207, 619-629.	3.1	5
69	Pure-tone auditory thresholds are decreased in depressed people with post-traumatic stress disorder. Journal of Affective Disorders, 2010, 127, 169-176.	4.1	10
70	Orodispersible sublingual piribedil to abort OFF episodes: A single dose placeboâ€controlled, randomized, doubleâ€blind, crossâ€over study. Movement Disorders, 2010, 25, 368-376.	3.9	21
71	Differential patterns of initial and sustained responses in amygdala and cortical regions to emotional stimuli in schizophrenia patients and healthy participants. Journal of Psychiatry and Neuroscience, 2010, 35, 41-48.	2.4	24
72	Difficultés cliniques dans les maladies raresÂ: comment les leverÂ?. Presse Medicale, 2010, 39, 51-52.	1.9	0

#	Article	IF	CITATIONS
73	Dopaminergic modulation of the default mode network in Parkinson's disease. European Neuropsychopharmacology, 2010, 20, 784-792.	0.7	105
74	Effect of ascorbic acid in patients with Charcot–Marie–Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2009, 8, 1103-1110.	10.2	114
75	Cognitive impulsivity in Parkinson's disease patients: Assessment and pathophysiology. Movement Disorders, 2009, 24, 2316-2327.	3.9	32
76	Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies. Psychopharmacology, 2009, 207, 201-212.	3.1	12
77	Hemodynamic, autonomic and baroreflex changes after one night sleep deprivation in healthy volunteers. Autonomic Neuroscience: Basic and Clinical, 2009, 145, 76-80.	2.8	49
78	Risperidone versus haloperidol for facial affect recognition in schizophrenia: Findings from a randomised study. World Journal of Biological Psychiatry, 2009, 10, 719-728.	2.6	25
79	Dopaminergic Modulation of Amygdala Activity During Emotion Recognition in Patients With Parkinson Disease. Journal of Clinical Psychopharmacology, 2009, 29, 548-554.	1.4	37
80	Analysis of the benefits of vitamin cocktails in treating Charcot–Marie–Tooth disease type 1A. Muscle and Nerve, 2008, 38, 1052-1054.	2.2	10
81	Neural bases of different cognitive strategies for facial affect processing in schizophrenia. Schizophrenia Research, 2008, 100, 191-205.	2.0	129
82	Evidence of a Decrease in Heart Rate and Skin Conductance Responses in PTSD Patients After a Single EMDR Session. Journal of EMDR Practice and Research, 2008, 2, 51-56.	0.6	32
83	Amygdala Activation Modulated by Levodopa During Emotional Recognition Processing in Healthy Volunteers. Journal of Clinical Psychopharmacology, 2007, 27, 692-697.	1.4	24
84	Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscular Disorders, 2007, 17, 248-253.	0.6	67
85	Use of albumin in three French university hospitals: is prescription monitoring still useful in 2004?. Pharmacoepidemiology and Drug Safety, 2007, 16, 79-85.	1.9	8
86	Influence of visual cues on gait in Parkinson's disease: Contribution to attention or sensory dependence?. Journal of the Neurological Sciences, 2006, 248, 192-195.	0.6	125
87	Erratum. Clinical Neuropharmacology, 2006, 29, 185.	0.7	15
88	A Double-blind, Placebo- and Flurazepam-controlled Investigation of the Residual Psychomotor and Cognitive Effects of Modified Release Zolpidem in Young Healthy Volunteers. Journal of Clinical Psychopharmacology, 2006, 26, 284-289.	1.4	29
89	Brain T1 intensity changes after levodopa administration in healthy subjects: a voxel-based morphometry study. British Journal of Clinical Pharmacology, 2006, 62, 546-551.	2.4	36
90	Dopaminergic Contribution to the Regulation of Emotional Perception. Clinical Neuropharmacology, 2005, 28, 228-237.	0.7	121

#	Article	IF	CITATIONS
91	Pergolide. Clinical Neuropharmacology, 2005, 28, 120-125.	0.7	14
92	Effect of Levodopa on Healthy Volunteers' Facial Emotion Perception. Clinical Neuropharmacology, 2005, 28, 255-261.	0.7	38
93	An additive factor analysis of the effect of depression on the reaction time of old patients. Acta Psychologica, 2004, 117, 1-11.	1.5	22
94	A study of a topiramate pre-treatment on the effects induced by a subanaesthetic dose of ketamine on human reaction time. Neuroscience Letters, 2004, 369, 99-103.	2.1	5
95	An electromyographic analysis of the effect of levodopa on the response time of healthy subjects. Psychopharmacology, 2003, 165, 313-316.	3.1	16
96	Risk propensity in commercial and military pilots. Aviation, Space, and Environmental Medicine, 2003, 74, 879-81.	0.5	8
97	Effects of Subanesthetic Doses of Ketamine on Sensorimotor Information Processing in Healthy Subjects. Clinical Neuropharmacology, 2002, 25, 101-106.	0.7	24
98	Dopamine and human information processing: a reaction-time analysis of the effect of levodopa in healthy subjects. Psychopharmacology, 2002, 163, 62-67.	3.1	39
99	N-methyl-?-aspartate receptors and information processing: human choice reaction time under a subanaesthetic dose of ketamine. Neuroscience Letters, 2001, 303, 29-32.	2.1	22
100	Neurobiology and Clinical Pharmacology of Obsessive-Compulsive Disorder. Clinical Neuropharmacology, 2001, 24, 191-207.	0.7	68
101	Levodopa-induced Drowsiness in Healthy Volunteers: Results of a Choice Reaction Time Test Combined with a Subjective Evaluation of Sedation. Clinical Neuropharmacology, 2001, 24, 91-94.	0.7	20
102	Pharmacokinetic and Pharmacodynamic Analysis of Sedative and Amnesic Effects of Lorazepam in Healthy Volunteers. Clinical Neuropharmacology, 2001, 24, 71-81.	0.7	34
103	Controlled Trial of 3-Day Quinine-Clindamycin Treatment versus 7-Day Quinine Treatment for Adult Travelers with Uncomplicated Falciparum Malaria Imported from the Tropics. Antimicrobial Agents and Chemotherapy, 2001, 45, 932-935.	3.2	40
104	Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorption of IS-159, a peptide serotonin 1B/1D-receptor agonist. Clinical Pharmacology and Therapeutics, 2000, 68, 114-121.	4.7	9
105	Effects of Lorazepam on Emotional Reactivity, Performance, and Vigilance in Subjects With High or Low Anxiety. Journal of Clinical Psychopharmacology, 2000, 20, 226-233.	1.4	8
106	Serotonin and human information processing: an electromyographic study of the effects of fluvoxamine on choice reaction time. Neuroscience Letters, 1999, 265, 143-146.	2.1	15
107	A Comparative Review of New Antipsychotics. Canadian Journal of Psychiatry, 1999, 44, 235-244.	1.9	98
108	Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology, 1997, 7, 125-137.	0.7	247

#	ARTICLE	IF	CITATION
109	Serotonin and human information processing: fluvoxamine can improve reaction time performance. Neuroscience Letters, 1997, 229, 204-208.	2.1	56
110	Antipsychotic and Anxiolytic Properties of Risperidone, Haloperidol, and Methotrimeprazine in Schizophrenic Patients. Journal of Clinical Psychopharmacology, 1996, 16, 38-44.	1.4	100
111	Contrast sensitivity improvement with sulfamethoxazole and trimethoprim in a patient with Machado-Joseph disease without spasticity. Journal of the Neurological Sciences, 1994, 123, 95-99.	0.6	9
112	Low luminance contrast sensitivity: Effects of training on psychophysical and optokinetic nystagmus thresholds in man. Vision Research, 1994, 34, 1893-1899.	1.4	5
113	A comparison between the effect of intentional modulations and the action of l-Dopa on gait in Parkinson's disease. Behavioural Brain Research, 1991, 45, 177-183.	2.2	42
114	Apomorphine-Induced Yawning in Migraine Patients. Clinical Neuropharmacology, 1991, 14, 91.	0.7	49